Biopharma has invested billions in modernizing drug discovery and commercial manufacturing. AI, machine learning, high-throughput experimentation, and advanced production capabilities are transforming both ends of the value chain. Yet between these sophisticated endpoints sits a historically underfunded vulnerability: Chemistry, Manufacturing, and Controls (CMC).

CMC has become the industry’s proverbial “Strait of Hormuz,” a narrow and often unpredictable checkpoint through which every therapy must pass before reaching patients. The consequences are significant. CMC deficiencies have contributed to 74% of FDA Complete Response Letters, often because of fragmented evidence, unresolved site observations, weak manufacturing readiness, or incomplete proof of commercial-scale control.

Solving this challenge requires more than isolated technology deployments. By connecting scientific data, redesigning workflows, and applying agentic orchestration and AI-enabled process intelligence, biopharma companies could reduce overall cycle times by up to 40% and accelerate individual phases by as much as 60%.